NIH Ends Gene Therapy Trial Reporting Requirements In Reg Streamlining Move
Trial protocols, annual reports, and adverse event reports on gene therapies now only go to US FDA, a signal that the products can be regulated like other drugs and biologics.
You may also be interested in...
CBER Director Peter Marks says the "half-life" for the existing six gene therapy guidances likely is two to three years due to the fast pace of scientific discovery.
Streamlining adverse event reports among reform ideas; NIH's Recombinant DNA Advisory Committee likely to drop review of more routine protocols.
INTERACT program will allow sponsors to ask FDA questions about manufacturing and other technical issues to help streamline development.